Tag: non-small cell lung cancer

1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC). 2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients...
1. Progression free survival and overall survival was significantly increased in patients who received pembrolizumab vs. patients who received platinum-based chemotherapy. 2. Treatment related toxicities were nearly doubled in the chemotherapy group vs. the pembrolizumab group. Evidence Rating Level: 1 (Excellent)  Study Rundown: Pembrolizumab is a humanized monoclonal antibody against programmed death...
1. Patients with advanced EGFR-associated non-small-cell lung cancer treated with dacomitinib had increased progression-free survival as compared to those without mutations. 2. Common adverse side effects including diarrhea, dermatitis, dry skin, and stomatitis were comparable to those of first generation tyrosine kinase inhibitors. Evidence Rating Level: 1 (Excellent) Study Rundown: Tyrosine kinase...
1. Brachytherapy following sublobar resection (BSR) had no significant association with local NSCLC recurrence compared to sublobar resection (SR) alone. 2. Three-year overall survival rates were similar between BSR and SR. Evidence rating level: 1 (Excellent) Study Rundown: Compared to lobectomy, sublobar resection for non-small-cell lung cancer (NSCLC) is associated with greater...
Image: PD  1. In this meta-analysis, progression-free survival was longer with conventional chemotherapy compared to epidermal growth factor receptor inhibitor tyrosine kinase inhibitors in individuals with stage IIIB and IV non-small cell lung cancer without epidermal growth factor receptor gene mutations.  2. In this meta-analysis, overall survival was no different with...
Image: PD  1. There was a 58% response rate to ceritinib among non-small-cell lung cancer (NSCLC) patients.  2. Median progression-free survival among patients with NSCLC on ceritinib was 7.0 months.  3. Ceritinib was effective in patients who had previously failed treatment with the currently approved ALK inhibitor, crizotinib.   Evidence Rating Level: 2 (Good)  Study...
Image: PD 1. Pleural effusions were associated with worse survival in non-small-cell lung cancer (NSCLC), particularly when they arose in early stage disease. Evidence rating level: 2 (Good) Study Rundown: Malignant pleural effusion containing malignant cells helps to define metastatic staging of lung cancer; however, diagnostic thoracentesis and pleural biopsy are not...